An early-stage healthcare AI company had strong mission alignment, a 30,000+ professional community, and a live NHS pilot.
The product wasn’t the issue.
Commercial sequencing was.
The challenges:
• Unclear enterprise procurement pathway
• Validation not framed institutionally
• Valuation tension ahead of raise
• Narrative drifting toward “AI tool” vs infrastructure
My role was not to polish a deck.
It was to restructure commercial positioning.
We:
• Reframed the NHS pilot as institutional validation anchor
• Clarified B2B procurement sequencing
• Pressure-tested valuation logic
• Sharpened investor segmentation
• Shifted positioning toward workforce infrastructure
The result was a clearer capital pathway and materially stronger investor articulation.
Strong product gets attention.
Structured commercial framing gets capital.
Fractional CRO | GTM Structuring | Revenue Discipline
Leave a Reply